A lthough new oral anticoagulants are replacing warfarin for stroke prevention in atrial fibrillation and for the prevention and treatment of venous thromboembolism, the lack of antidotes is a concern. Consequently, the development of a potential antidote for oral factor Xa inhibitors, such as rivaroxaban and apixaban, represents a major breakthrough.
A lthough new oral anticoagulants are replacing warfarin for stroke prevention in atrial fibrillation and for the prevention and treatment of venous thromboembolism, the lack of antidotes is a concern. Consequently, the development of a potential antidote for oral factor Xa inhibitors, such as rivaroxaban and apixaban, represents a major breakthrough.
For decades, vitamin K antagonists (VKAs), such as warfarin, were the only orally available anticoagulants. This situation changed with the recent introduction of oral direct thrombin and factor Xa inhibitors. Designed to be given in fixed doses without laboratory monitoring, the new oral anticoagulants (NOACs) are more convenient to administer than warfarin. When compared with warfarin in large phase III clinical trials, NOACs were at least as effective as warfarin, but were associated with less intracranial bleeding. Despite these advantages, however, some clinicians are reluctant to use NOACs because specific antidotes are lacking. In a recent report in Nature Medicine, Lu et al have taken the first step to addressing this unmet medical need. These investigators developed a bioengineered recombinant variant of factor Xa that serves as an antidote for oral and parenteral factor Xa inhibitors. Not only does the antidote reverse the anticoagulant effect of oral factor Xa inhibitors in vitro and in animals, but it also reduces blood loss induced by these agents in rat tail transection and rabbit liver laceration bleeding models. Based on these promising results, the antidote is now undergoing phase II evaluation in humans. If the preclinical findings are confirmed in humans, this antidote has the potential to increase usage of the oral factor Xa inhibitors and streamline their management in situations where rapid reversal is needed in preparation for urgent surgery or intervention, or in patients with serious bleeding.
Oral anticoagulants are used for long-term prevention and treatment of venous and arterial thrombosis. Although effective, VKAs have well-documented limitations, including a slow onset of action, variable dose requirements, multiple food and drug interactions, and a narrow therapeutic window, which necessitates monitoring of the international normalized ratio to ensure that the level of anticoagulation is therapeutic, and frequent dose adjustments to achieve this level. The complexity of management likely contributes to the systematic underuse of VKAs for stroke prevention in eligible patients with atrial fibrillation. 1 Furthermore, in patients receiving VKAs for this and other indications, the international normalized ratio is often outside the therapeutic range. 2 NOACs were developed to overcome the limitations of VKAs. In contrast to VKAs, which lower the levels of multiple coagulation factors, NOACs only have a single target; dabigatran inhibits thrombin, whereas rivaroxaban and apixaban inhibit factor Xa. Selective targeting endows NOACs with a wider therapeutic window than VKAs, thereby enabling administration in fixed doses without coagulation monitoring. Consequently, NOACs are more convenient to administer than VKAs. 3 When compared with warfarin in patients with atrial fibrillation or venous thromboembolism, NOACs were at least as effective for prevention of stroke and recurrent venous thromboembolism, respectively, but were associated with a significant reduction in the rate of intracranial hemorrhage, the most feared complication of anticoagulation therapy. [4] [5] [6] Rates of extracranial bleeding with NOACs were similar or lower than those with warfarin, providing additional evidence of the safety of NOACs.
Based on the results of the phase III trials, dabigatran, rivaroxaban, and apixaban are licensed as alternatives to warfarin for stroke prevention in patients with atrial fibrillation, and clinical guidelines give preference to NOACs over warfarin for this indication. [7] [8] [9] Rivaroxaban is also approved for prevention and treatment of venous thromboembolism and, in Europe, for prevention of recurrent ischemia in patients with stabilized acute coronary syndrome. 10, 11 Dabigatran is under regulatory review for the treatment of acute venous thromboembolism, and apixaban is likely to soon follow suit. With the ever expanding indications for NOACs, their usage is increasing exponentially.
Despite the advantages of NOACs, some clinicians continue to prescribe VKAs because of concern about the lack of specific antidotes for NOACs. Although the short half-life of the NOACs obviates the need for an antidote in most situations, there still is the worry that patients taking NOACs will be disadvantaged should they develop serious bleeding or require urgent surgery or intervention. 12, 13 Consequently, development of specific antidotes for NOACs has emerged as a priority. A humanized mouse monoclonal antibody fragment is under development as a specific antidote for dabigatran. 14 A different approach has been taken to reverse the oral factor Xa inhibitors. In a recent report in Nature Medicine, Lu et al 15 describe a bioengineered recombinant variant of factor Xa expressed in Chinese hamster ovary cells that serves as an antidote not only for oral factor Xa inhibitors, but also for parenteral factor Xa inhibitors, such as enoxaparin, a low-molecular-weight heparin, and fondaparinux, a synthetic pentasaccharide that binds antithrombin with high affinity. To understand the mechanism of action of this antidote, termed r-Antidote, it is helpful to first review the role of factor Xa in clotting and examine how oral and parenteral factor Xa inhibitors attenuate this process. Tissue factor exposed at sites of vascular injury binds factor VIIa, and the tissue factor/factor VIIa complex then activates factor X. Factor Xa, together with its cofactor factor Va, assembles on the surface of activated platelets to form prothrombinase, the enzyme complex that activates prothrombin to thrombin. Oral factor Xa inhibitors attenuate fibrin clot formation by blocking prothrombinase-mediated thrombin generation. Administered as active drug, these small molecules are absorbed from the gastrointestinal tract and enter the circulation where a large proportion is bound to albumin. It is the free drug that exerts anticoagulant activity by reversibly inhibiting the active site of factor Xa that is incorporated into prothrombinase (Figure, A) .
Oral factor Xa inhibitors are direct inhibitors because they bind directly to factor Xa and do not require a plasma cofactor to exert their anticoagulant activity. In contrast, parenteral factor Xa inhibitors, such as enoxaparin and fondaparinux, are indirect inhibitors because they lack intrinsic anticoagulant activity. Instead, these agents act as anticoagulants by binding antithrombin, a naturally circulating inhibitor, and promoting its capacity to inhibit factor Xa (Figure, B) . Whereas factor Xa incorporated into prothrombinase is readily inhibited by direct factor Xa inhibitors, it is partially protected from inhibition by indirect inhibitors. The capacity to inhibit factor Xa in prothrombinase may render direct factor Xa inhibitors more potent antithrombotic drugs than indirect factor Xa inhibitors.
What is the structure of r-Antidote and how does it reverse factor Xa inhibitors? r-Antidote is a bioengineered variant of native factor Xa that serves as a decoy for small-molecule direct factor Xa inhibitors (Figure, C). To accomplish this task, the antidote must have no intrinsic procoagulant or anticoagulant activity and must bind direct factor Xa inhibitors with affinity similar to that of native factor Xa. To prevent procoagulant activity, the active site serine residue in r-Antidote was Figure. Mechanism of action of r-Antidote. A, The prothrombinase complex, which consists of factor Xa and its cofactor factor Va, assembles on a membrane surface where it converts prothrombin (II) to thrombin (IIa). The membrane-binding Gla-domain (hatched oval) and active site serine (S) of factor Xa are essential for factor Xa function. Factor Xa-directed new oral anticoagulants (NOACs) bind reversibly to the active site of factor Xa and attenuate its capacity to activate II. B, Fondaparinux, a synthetic pentasaccharide, binds antithrombin (AT) and catalyzes the inhibition of factor Xa, thus attenuating prothrombin activation. C, r-Antidote, which has its active serine converted to alanine (A) to prevent procoagulant activity, binds the NOACs, but does not compete with factor Xa for incorporation into the prothrombinase complex because it lacks the membrane-binding Gla-domain. By binding NOACs, r-Antidote reverses factor Xa inhibition and restores that capacity of prothrombinase to generate thrombin and to effect hemostasis. D, r-Antidote competes with factor Xa for fondaparinux-activated antithrombin, thereby allowing prothrombinase to generate thrombin.
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replaced with alanine. Consequently, unlike native factor Xa, the antidote is unable to cleave factor Xa-directed chromogenic substrates or to generate thrombin in plasma. Without catalytic activity, the antidote could still exhibit anticoagulant activity by competing with native factor Xa for incorporation into prothrombinase. To circumvent this problem, r-Antidote was expressed without a membrane-binding Gla-domain. The success of this maneuver is evidenced by the fact that even at high concentrations, r-Antidote did not prolong the prothrombin time. Does mutation of the active site serine residue and deletion of the membrane-binding domain reduce the capacity of the antidote to bind factor Xa inhibitors? Based on kinetic assays, the answer is no; the antidote binds several direct factor Xa inhibitors with affinity similar to that of native factor Xa. The antidote reverses indirect factor Xa inhibitors through a different mechanism. Instead of directly binding the drug, r-Antidote serves as a decoy for activated antithrombin (Figure, D) , as evidenced by a reduction in the enoxaparin-or fondaparinux-catalyzed rate of factor Xa inhibition by antithrombin. Because it only competes with factor Xa for antithrombin binding, the antidote is likely to be more effective for reversal of fondaparinux, which only inhibits factor Xa, than for enoxaparin, which, in addition to inhibiting factor Xa, also inhibits thrombin.
In vitro studies were performed to examine the capacity of r-Antidote to reverse the anticoagulant effect of direct and indirect factor Xa inhibitors. The antidote reverses oral factor Xa inhibitor-induced prolongation of prothrombin time in a concentration-dependent fashion and attenuates the anti-factor Xa activity of both direct and indirect factor Xa inhibitors. Rat and rabbit bleeding models were then used to determine whether reversal of anticoagulant activity is associated with reduced blood loss. In rats given rivaroxaban, apixaban, or betrixaban, another oral factor Xa inhibitor, r-Antidote not only reversed the anticoagulant effect, but also attenuated tail bleeding. Although the antidote also reduced tail bleeding in rats given aspirin plus fondaparinux, it had less of an effect in rats given aspirin plus enoxaparin, likely reflecting the fact that the antidote reverses the anti-factor Xa activity of enoxaparin, but not its inhibitory activity against thrombin. Tail bleeding, however, may not mimic bleeding that occurs with major injury. To evaluate the use of the antidote to attenuate serious bleeding, r-Antidote was compared with saline in rivaroxaban-treated rabbits subjected to liver lacerations. The antidote reduced blood loss in this model as well, thereby highlighting its potential to manage even major organ bleeding.
What are the hurdles ahead for bringing r-Antidote to the clinic? Although billed as an antidote for both parenteral and oral factor Xa inhibitors, the major unmet medical need is an antidote for the oral factor Xa inhibitors. Finding the right dose of r-Antidote for this indication will be a challenge. The antidote only binds and reduces the free fraction of oral factor Xa inhibitor in the circulation; the total concentration of factor Xa inhibitor in the circulation increases with r-Antidote administration as the drug moves from the extravascular to the intravascular compartment. Because free drug levels are higher with once-daily oral factor Xa inhibitor dosing regimens than with twice-daily dosing regimens, and the oral factor Xa inhibitors differ in their volume of distribution and the extent to which they bind albumin, it is likely that each agent will require a unique antidote-reversal regimen.
Once the optimal dosing regimen is established, the next step will be to show that r-Antidote is efficacious. In addition to demonstrating that the antidote reverses anticoagulant activity in patients taking oral factor Xa inhibitors, as evidenced by a reduction in anti-factor Xa activity, regulatory agencies may also demand evidence that the antidote reduces bleeding and blood transfusion requirements. Demonstrating decreased bleeding will be difficult because life-threatening hemorrhage is uncommon with oral factor Xa inhibitors and because bleeding can continue despite anticoagulant reversal in some patients, such as those with intracerebral bleeding or those with multiple trauma.
What about evidence of safety? First, it will be important to show that the risk of stroke or other thromboembolic events does not increase with r-Antidote administration. Assessing the risk with the antidote is complicated by the fact that the background rate of thrombotic events increases whenever anticoagulants are reversed or withheld in patients at risk for such events. Consequently, demonstrating an increased risk on top of this background will be challenging. Nonetheless, it is important to do so because r-Antidote has the potential to induce thromboembolic events because of its off-target effect on tissue factor pathway inhibitor, a natural regulator of hemostasis. Tissue factor pathway inhibitor inhibits the tissue factor/factor VIIa complex by forming a quaternary complex together with factor Xa. r-Antidote reduces tissue factor pathway inhibitor activity by competing with native factor Xa for binding, thus producing a transient procoagulant state, which could increase the risk of thromboembolic events. 16 Fortunately, this procoagulant state is attenuated when r-Antidote is given to subjects taking oral factor Xa inhibitors because the NOACs compete with tissue factor pathway inhibitor for binding to r-Antidote. 16 Although it is reassuring that no thromboembolic events have been reported in the phase I and II studies conducted with r-Antidote to date, more data are needed.
The final safety concern relates to immunogenicity, which is a real possibility given that r-Antidote is a variant of endogenous factor Xa. Demonstrating a lack of immunogenicity will include ruling out the formation of antibodies against the antidote, which could preclude its readministration, and excluding the production of antibodies that crossreact with factor X or factor Xa, which could inhibit coagulation and induce bleeding. It is unlikely that r-Antidote is immunogenic because no antibodies have been detected in the studies conducted thus far.
In summary, the study by Lu et al 15 represents an important first step in the development of an antidote for factor Xa inhibitors. Although there are many challenges ahead, this elegant work identifies r-Antidote as a promising reversal agent for oral factor Xa inhibitors. We look forward to the results as r-Antidote moves along the clinical development pathway. 
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